ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.188,34
-1,00%
S&P 500
5.214,08
0,51%
US Dollar vs BRL
5,1422
1,04%
Bitcoin
62.989,91
2,93%
Brent Oil
83,95
0,47%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Precision BioSciences Inc (DTIL)

  7. Precision BioSciences Inc (DTIL) Notícias

DTIL

Precision BioSciences (DTIL)

Precision BioSciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:DTIL
DataHoraFonteTítuloCódigoCompanhia
08/05/202421:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
08/05/202409:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
08/05/202409:15Business WirePrecision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private PlacementNASDAQ:DTILPrecision BioSciences Inc
07/05/202417:30Business WirePrecision BioSciences to Report First Quarter Results on May 13, 2024NASDAQ:DTILPrecision BioSciences Inc
07/05/202409:30Business WirePrecision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
01/05/202408:05Business WirePrecision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024NASDAQ:DTILPrecision BioSciences Inc
16/04/202417:15Business WirePrecision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail TherapeuticsNASDAQ:DTILPrecision BioSciences Inc
27/03/202407:45Business WirePrecision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business UpdateNASDAQ:DTILPrecision BioSciences Inc
20/03/202417:30Business WirePrecision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024NASDAQ:DTILPrecision BioSciences Inc
19/03/202408:00Business WirePrecision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial MyopathyNASDAQ:DTILPrecision BioSciences Inc
06/03/202410:45Business WirePrecision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC DeficiencyNASDAQ:DTILPrecision BioSciences Inc
01/03/202408:30Business WirePrecision BioSciences Announces $40.0 Million Offering of Common Stock and WarrantsNASDAQ:DTILPrecision BioSciences Inc
01/03/202408:00Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:DTILPrecision BioSciences Inc
29/02/202419:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DTILPrecision BioSciences Inc
29/02/202418:01Business WirePrecision BioSciences Announces Proposed Public Offering of Common Stock and WarrantsNASDAQ:DTILPrecision BioSciences Inc
20/02/202409:00Business WirePrecision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou BiosciencesNASDAQ:DTILPrecision BioSciences Inc
14/02/202409:00Business WirePrecision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical ReadinessNASDAQ:DTILPrecision BioSciences Inc
13/02/202409:00Business WirePrecision BioSciences Promotes Naresh Tanna to Vice President of Investor RelationsNASDAQ:DTILPrecision BioSciences Inc
12/02/202413:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DTILPrecision BioSciences Inc
12/02/202409:00Business WirePrecision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune DiseasesNASDAQ:DTILPrecision BioSciences Inc
09/02/202409:00Business WirePrecision BioSciences to Effect a Reverse Stock SplitNASDAQ:DTILPrecision BioSciences Inc
23/01/202418:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
12/01/202410:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DTILPrecision BioSciences Inc
09/01/202411:20AllPennyStocks.comBiotech Massively Bid Up Before Opening BellNASDAQ:DTILPrecision BioSciences Inc
09/01/202409:00GlobeNewswire Inc.TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune DiseasesNASDAQ:DTILPrecision BioSciences Inc
09/01/202409:00Business WirePrecision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune DiseasesNASDAQ:DTILPrecision BioSciences Inc
13/12/202310:20Business WirePrecision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURENASDAQ:DTILPrecision BioSciences Inc
04/12/202318:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:DTILPrecision BioSciences Inc
04/12/202309:00Business WirePrecision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial DiseasesNASDAQ:DTILPrecision BioSciences Inc
30/11/202309:00Business WirePrecision BioSciences to Present at Hep-DART 2023NASDAQ:DTILPrecision BioSciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:DTIL

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
PDTC3
Padtec ON
BOV
OIBR3
OI ON
BOV
AZEV4
AZEVEDO PN
BOV
VVEO3
CM Hospitalar ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
PRIO3
PETRORIO ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
ENJU3
Enjoei ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
ENAT3
ENAUTA ON
BOV
JHSF3
JHSF PART ON
BOV
SGPS3
SPRINGS ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados